An overview of stereotactic body radiation therapy for hepatocellular carcinoma
Expert Review of Gastroenterology and Hepatology 14 巻 4 号
271-279 頁
2020-03-30 発行
アクセス数 : 352 件
ダウンロード数 : 209 件
今月のアクセス数 : 3 件
今月のダウンロード数 : 4 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00051079
ファイル情報(添付) |
ExpRevGastroHepatol_14_271.pdf
500 KB
種類 :
全文
|
タイトル ( eng ) |
An overview of stereotactic body radiation therapy for hepatocellular carcinoma
|
作成者 |
Takahashi Sigeo
Kubo Katsumaro
Imano Nobuki
Nishibuchi Ikuno
Kenjo Masahiro
|
収録物名 |
Expert Review of Gastroenterology and Hepatology
|
巻 | 14 |
号 | 4 |
開始ページ | 271 |
終了ページ | 279 |
抄録 |
Introduction: According to several guidelines, stereotactic body radiation therapy (SBRT) for early hepatocellular carcinoma (HCC) can be considered an alternative to other modalities, such as resection, radiofrequency ablation (RFA), and transarterial chemoembolization (TACE), or when these therapies have failed or are contraindicated. This article reviews the current status of SBRT for the treatment of HCC.
Areas covered: From the results of many retrospective reports, SBRT is a promising modality with an excellent local control of almost 90% at 2–3 years and acceptable toxicities. Currently there are no randomized trials to compare SBRT and other modalities, such as resection, RFA, and TACE, but many retrospective reports and propensity score matching have shown that SBRT is comparable to the different modalities. Repeated SBRT for intra-hepatic recurrent HCC also resulted in high local control with safety and satisfactory overall survival, which were comparable to those of other curative local treatments. Expert opinion: Despite the good results of SBRT, the conclusions of the comparisons of SBRT and other modalities are still controversial. Further studies, including randomized phase III studies to define that patients are more suitable for each curative local treatment, are needed. |
著者キーワード |
Stereotactic body radiotherapy (SBRT)
hepatocellular carcinoma (HCC)
resection
radiofrequency ablation (RFA)
transarterial chemoembolization (TACE)
|
言語 |
英語
|
資源タイプ | 学術雑誌論文 |
出版者 |
Taylor and Francis
|
発行日 | 2020-03-30 |
権利情報 |
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Gastroenterology and Hepatology on 30 Mar 2020, available online: http://www.tandfonline.com/10.1080/17474124.2020.1744434.
This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
|
出版タイプ | Author’s Original(十分な品質であるとして、著者から正式な査読に提出される版) |
アクセス権 | オープンアクセス |
収録物識別子 |
[ISSN] 1747-4124
[ISSN] 1747-4132
[DOI] 10.1080/17474124.2020.1744434
[DOI] https://doi.org/10.1080/17474124.2020.1744434
|